This Article Full Text Full Text (PDF) All Versions of this Article: 91/10/3773    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brooke, A. M. Articles by Monson, J. P. Search for Related Content PubMed PubMed Citation Articles by Brooke, A. M. Articles by Monson, J. P. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Hormone Replacement Therapy Related Collections Adrenal and Hypertension Female Endocrinology Male Endocrinology Neuroendocrinology and Pituitary

Dehydroepiandrosterone Improves Psychological Well-Being in Male and Female Hypopituitary Patients on Maintenance Growth Hormone Replacement

Centre for Clinical Endocrinology, William Harvey Research Institute, St. Bartholomew’s Hospital, London EC1A 7BE, United Kingdom

Address all correspondence and requests for reprints to: Professor J. P. Monson, Department of Endocrinology, St. Bartholomew’s Hospital, West Smithfield, London EC1A 7BE, United Kingdom. E-mail: j.p.monson{at}qmul.ac.uk.

Context: Patients with panhypopituitarism have impaired quality of life (QoL) despite GH replacement. They are profoundly androgen deficient, and dehydroepiandrosterone (DHEA) has been shown to have a beneficial effect on well-being and mood in patients with adrenal failure and possibly in hypopituitarism.

Objective: Our objective was to determine the effect of DHEA administration on mood in hypopituitary adults on established GH replacement with a constant serum IGF-I.

Design: A double-blind, placebo-controlled trial was conducted over an initial 6 months followed by an open phase of 6 months of DHEA.

Setting: The study was conducted at a tertiary referral endocrinology unit.

Patients: Thirty female and 21 male hypopituitary patients enrolled. Data from 26 females and 18 males were analyzed after patient withdrawal.

Interventions: DHEA (50 mg) was added to maintenance replacement including GH.

Main Outcome Measures: The primary outcome objective was the effect on QoL and libido assessed by QoL assessment in GH deficiency in adults, Short Form 36, General Health Questionnaire, EuroQol, and sexual self-efficacy scale.

Results: Patients had impaired QoL at baseline compared with the age-matched British population. Females showed improvement in QoL assessment in GH deficiency in adults score (–2.9 ± 2.8 DHEA vs.–0.53 ± 3 placebo; P < 0.05), in Short Form 36 social functioning (14.6 ± 23.1 DHEA vs.–4.7 ± 25 placebo; P = 0.047), and general health perception (9.6 ± 14.2 DHEA vs.–1.2 ± 11.6 placebo; P = 0.036) after 6 months of DHEA. Men showed improvement in self-esteem (–1.3 ± 1.7 DHEA vs. 0.5 ± 1.5 placebo; P = 0.03) and depression (–1.6 ± 2.2 DHEA vs. 1.2 ± 2.4 placebo, P = 0.02) domains of the General Health Questionnaire after 6 months of DHEA.

Conclusions: DHEA replacement leads to modest improvement in psychological well-being in female and minor psychological improvement in male hypopituitary patients on GH replacement.

This article has been cited by other articles:

				S. Hahner, M. Loeffler, M. Fassnacht, D. Weismann, A.-C. Koschker, M. Quinkler, O. Decker, W. Arlt, and B. Allolio Impaired Subjective Health Status in 256 Patients with Adrenal Insufficiency on Standard Therapy Based on Cross-Sectional Analysis J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3912 - 3922. [Abstract] [Full Text] [PDF]